casopitant

Phase 3Small molecule

casopitant is one of 57 small molecule programs targeting Post Operative Nausea and Vomiting. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Post Operative Nausea and VomitingActive, not recruiting

Nausea and VomitingActive, not recruiting

Post Operative Nausea and VomitingPhase 3

Active, not recruiting

Nausea and VomitingPhase 3

Active, not recruiting

Competition

Competitive Landscape

224 competitors in Nausea and Vomiting

#DrugCompanyPhaseTrials

casopitant

GSK

Phase 3

2 2

Aloxi

AAvyxa

Preclinical

27 3

Alfenta

Alnylam Pharmaceuticals

Preclinical

1 4

Ramosetron

Astellas

Preclinical

15 5

Phenergan

BBassett Healthcare

Preclinical

5 6

Haldol

DDePuy Orthopaedics

Preclinical

3 7

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 8

Versed

CConrado Roberto Hoffmann Filho

Preclinical

2 9

Anerem

AAcacia Pharma Ltd

Preclinical

2 10

Oxycontin

PProtega

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Nausea and vomiting2 trials

A Study Of IV Casopitant For The Prevention Of Chemotherapy Induced Nausea And Vomiting.

Completed· GSK logo

GSK·Phase 3·NCT00601172·710 enrolled

Intravenous And Oral Casopitant (GW679769) For The Prevention Of Chemotherapy Induced Nausea And Vomiting

Completed· GSK logo

GSK·Phase 3·NCT00366834·1,840 enrolled

Interaction2 trials

The Pharmacokinetic Interaction Between Oral Casopitant and Oral Dolasetron, Granisetron or Rosiglitazone in Subjects

Completed· GSK logo

GSK·Phase 1·NCT00511823·16 enrolled

A Study to Assess the Safety and Interaction Between Casopitant and Ketoconazole When Taken By Healthy Adults

Completed· GSK logo

GSK·Phase 1·NCT00460707·85 enrolled

Post Operative Nausea and Vomiting1 trial

Casopitant And ZOFRAN To Prevent Post Operative Nausea And Vomiting In Women

Completed· GSK logo

GSK·Phase 3·NCT00334152·515 enrolled

Renal Impairment1 trial

Observational Pharmacokinetic Study Of GW679769 In Subjects With Renal Impairment

Completed· GSK logo

GSK·Phase 1·NCT00358813·18 enrolled

Nausea1 trial

A Study of the Drug Casopitant for the Prevention of Nausea Caused By Cisplatin-Based Highly Emetogenic Chemotherapy

Completed· GSK logo

GSK·Phase 3·NCT00431236·810 enrolled

3 more indications

Dexamethasone1 trial

A Study to Assess the Safety & Interaction Between GW679769, Dexamethasone, & Ondansetron When Taken by Healthy Adults

Completed· GSK logo

GSK·Phase 1·NCT00437229·37 enrolled

ESS1 trial

Study Of Healthy Subjects To Assess The Effect Of Ketoconazole And The Way The Body Will React To Casopitant [GW679769]

Completed· GSK logo

GSK·Phase 1·NCT00404378·15 enrolled

Unspecified1 trial

A Study Testing the Effect and Safety of Casopitant (GW679769) While Taking Warfarin in Healthy Human Volunteers

Completed· GSK logo

GSK·Phase 1·NCT00404274·97 enrolled

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for casopitant. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — casopitant compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for casopitant. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — GSK company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: GSK

casopitant

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Nausea and vomiting2 trials

Interaction2 trials

Post Operative Nausea and Vomiting1 trial

Renal Impairment1 trial

Nausea1 trial

Dexamethasone1 trial

ESS1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News